Unity生物技术公司公布了与糖尿病相关失明的研究的混合数据，股票下跌-动脉网

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

benzinga 等信源发布 2025-03-24 11:26



可切换为仅中文







Unity Biotechnology, Inc.

Unity Biotechnology公司

UBX

stock plummeted on Monday after the company released results

周一公司发布结果后，股票暴跌。

from its latest study

来自其最新的研究

。

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment.

玻璃体内注射UBX1325的2b期ASPIRE临床试验涉及尽管之前接受过抗VEGF治疗但视力仍然不佳的糖尿病性黄斑水肿（DME）患者。

The study results include data from all patients through 24 weeks and most

研究结果包括所有患者24周的数据以及大多数患者的后续数据。

patients through 36 weeks

36周的患者

。

UBX1325 treatment led to visual acuity gains of over 5 letters from baseline at weeks 24 and 36 and achieved non-inferiority to

UBX1325治疗在第24周和第36周时，相比基线视力提高了超过5个字母，并实现了非劣效性

Regeneraon Pharmaceuticals Inc’s

再生医药公司

REGN

再生元制药（Regeneron Pharmaceuticals）

Eylea (aflibercept) at 9 out of 10-time points through 36 weeks.

Eylea（阿柏西普）在36周内的10个时间点中，有9个时间点表现出效果。

Also Read:

另请阅读：

GE Aerospace Opens XEOS Facility To Power Up LEAP Engine Overhauls: Details

GE航空航天公司开设XEOS设施，助力LEAP发动机大修：详情

UBX1325-treated patients had a mean change in BCVA of +5.2 ETDRS letters from baseline to 24 weeks, representing a difference of +0.4 ETDRS letters compared to the aflibercept arm.

接受UBX1325治疗的患者从基线到24周的BCVA平均变化为+5.2个ETDRS字母，与阿柏西普组相比，差异为+0.4个ETDRS字母。

UBX1325-treated patients had a mean change in BCVA of +5.5 ETDRS letters from baseline to 36 weeks, representing a difference of +0.2 ETDRS letters compared to the aflibercept arm.

接受UBX1325治疗的患者从基线到36周的BCVA平均变化为+5.5个ETDRS字母，与阿柏西普组相比差异为+0.2个ETDRS字母。

UBX1325 was non-inferior to aflibercept at all time points through 36 weeks, except for the average of weeks 20 and 24

UBX1325在36周内的所有时间点均不劣于阿柏西普，但第20周和第24周的平均值除外。

Patients on UBX1325 had an increase in Central Subfield Thickness (CST) at weeks 16 and 20, which resulted in supplemental anti-VEGF treatments in patients with significant CST gain.

接受UBX1325治疗的患者在第16周和第20周中央亚区厚度（CST）增加，这导致了对CST显著增加的患者进行补充抗VEGF治疗。

UBX1325 generally outperformed aflibercept in patients who had moderate disease severity (baseline CST < 400 microns, representing ~60% of study patients) (pre-specified analysis)

在中度疾病严重程度（基线CST < 400微米，约占研究患者的60%）的患者中，UBX1325通常优于阿柏西普（预设分析）。

Patients who switched from aflibercept as their anti-VEGF treatment before study enrollment to UBX1325 had the most consistent and durable vision gains (pre-specified analysis)

在研究入组前从阿柏西普转换为UBX1325治疗的患者，其视力提升最为一致且持久（预设分析）。

UBX1325 continues to demonstrate a favorable safety and tolerability profile.

UBX1325 继续表现出良好的安全性和耐受性。

Unity anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Unity 预计剩余患者完整的 36 周数据结果将在 2025 年第二季度出炉。

As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $23.2 million, sufficient to fund operations

截至2024年12月31日，现金、现金等价物和可出售证券总计达2,320万美元，足以支持公司运营。

into the fourth quarter of 2025

进入2025年的第四季度

。

Price Action:

价格行为: